Pediatric antiarrhythmics and toxicity: A clinical review

Alexandra T Geanacopoulos1,2, Benjamin Zielonka2,3, Miriam T Fox2

  • 1Division of Emergency Medicine Boston Children's Hospital Boston Massachusetts USA.

Insights

Pediatric antiarrhythmic medications are crucial for managing heart rhythm disorders but can cause toxicity. Emergency clinicians need expertise in recognizing and treating adverse effects of these vital drugs.

Area of Science:

  • Pediatric Cardiology
  • Clinical Pharmacology
  • Emergency Medicine

Background:

  • Antiarrhythmic drugs are essential for treating pediatric arrhythmias.
  • Pediatric patients are susceptible to antiarrhythmic drug toxicities.
  • Effective management requires emergency medicine clinician proficiency.

Purpose of the Study:

  • To review the use of antiarrhythmic medications in children.
  • To detail the pharmacology and adverse effects of common pediatric antiarrhythmics.
  • To outline the toxicologic treatment of antiarrhythmic toxicity in pediatric patients.

Main Methods:

  • Clinical review of existing literature.
  • Focus on indications, pharmacology, and adverse effects.
  • Emphasis on toxicologic management strategies.

Main Results:

  • Commonly used antiarrhythmics in pediatrics have specific indications.
  • Each drug possesses a unique pharmacokinetic and pharmacodynamic profile.
  • Adverse effects range from mild to life-threatening, necessitating prompt intervention.

Conclusions:

  • Understanding antiarrhythmic pharmacology is key to safe pediatric use.
  • Vigilance for and prompt treatment of toxicity are critical in pediatric emergency care.
  • This review provides a resource for clinicians managing pediatric arrhythmias and their toxicities.

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
996
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
744
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
920